# Testing Two Different Drugs (Sacituzumab-govitecan and Trastuzumab-deruxtecan) Combinations Prescribed in an Alterning Pattern to Patients With Metastatic or Locally Advanced Triple-negative Breast Cancer

> **NCT07151586** · PHASE2 · NOT_YET_RECRUITING · sponsor: **UNICANCER** · enrollment: 260 (estimated)

## Conditions studied

- Triple Negative Breast Neoplasms
- Neoplasm Metastasis
- HER 2 Low-expressing Breast Cancer

## Interventions

- **DRUG:** Sacituzumab Govitecan / Trastuzumab Deruxtecan

## Key facts

- **NCT ID:** NCT07151586
- **Lead sponsor:** UNICANCER
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-10
- **Primary completion:** 2029-10
- **Final completion:** 2029-10
- **Target enrollment:** 260 (ESTIMATED)
- **Last updated:** 2025-09-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07151586

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07151586, "Testing Two Different Drugs (Sacituzumab-govitecan and Trastuzumab-deruxtecan) Combinations Prescribed in an Alterning Pattern to Patients With Metastatic or Locally Advanced Triple-negative Breast Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07151586. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*